Journal of Virology, October 2004, p. 11450, Vol. 78, No. 20
0022-538X/04/$08.00+0 DOI: 10.1128/JVI.78.20.11450.2004
| AUTHOR'S CORRECTION |
INSERM U544, Institut de Virologie, 67000 Strasbourg, and Maladies Infectieuses, Hospital Cochin, and Institut Pasteur, Paris, France
Volume 75, no. 11, p. 5421-5424, 2001. We were informed that three patients (referred to as 19, 26, and 29) had their treatment modified between inclusion and the subsequent plasma collection: a nonnucleoside reverse transcriptase inhibitor Efavirenz (EFV) had been added to their regiment. Thus, for two of them the nonimmunoglobulin inhibitory activity reported is related to EFV.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| J. Bacteriol. | Mol. Cell. Biol. | Microbiol. Mol. Biol. Rev. |
|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|